Siga Technologies Inc (SIGA) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket
 


Siga Technologies Inc  (NASDAQ: SIGA)


Siga Technologies Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Siga Technologies Inc's ROI in the third quarter of 2026?
Siga Technologies Inc achieved a return on average invested assets (ROI) of 8.91 % in its third quarter of 2026, which is below Siga Technologies Inc's average return on investment, which stands at 28.3%.

Despite the deterioration in its net income, company has improved ROI compared to the second quarter of 2026.

Within the Healthcare sector 133 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 475 to 820.

Definition and Formula of Return on Investment



Return On Investment (Sep 30 2026)
III. Quarter
(Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM -21.24 % -11.09 % 1.62 % 20.43 % 24.63 %
Y / Y Net Income Change TTM -79.07 % -85.26 % -56.67 % -50.58 % 5441.1 %
Investment (TTM) in Millions 166 168 154 212 217
Return On Investment (TTM) 8.91 % 6.45 % 10.04 % 10.57 % 33.53 %
SIGA's Overall Ranking # 820 # 475 # 521 # 146 #
Seq. Investment Change TTM -6.8 % -6.82 % -8.55 % -0.82 % 5.2 %
Seq. Net Income Change TTM 28.67 % -40.13 % -13.08 % -68.74 % -9.38 %
Net Income (TTM) in Millions 16 12 20 23 74




Return On Investment SIGA's Ranking
Within: No.
Industry # 49
Sector # 134
Overall # 820

Return On Investment Statistics
High Average Low
815.79 %
28.3 %
-239.96 %
(Dec 31 2018)   (Sep 30 2016)



  News about Siga Technologies Inc Return on Investment ROI

SIGA Technologies' Appoints Larry Miller as General Counsel, Ushering in a New Era of Legal Excellence in Pursuit of Health Security

March 25, 2024

Introducing Larry Miller: SIGA Technologies Latest Addition Bolsters Legal Team in Pursuit of Health Security Excellence
: March 25, 2024
Publication:
In the ever-evolving landscape of health security and infectious diseases, SIGA Technologies, Inc. (NASDAQ: SIGA), a leading commercial-stage pharmaceutical company, solidifies its commitment to excellence with the appointment of Larry Miller as its general counsel. Effective immediately, Miller brings a wealth of legal expertise and diverse industry experience to fortify SIGA s legal team, propelling the company to new heights in its pursuit of safeguarding global health.
SIGA Technologies has long been renowned for its cutting-edge research and development centered around health security measures and innovative solutions to combat infectious diseases. With the appointment of Larry Miller, the company advances its ambitious agenda, positioning itself as a frontrunner in the pharmaceutical industry s battle against emerging health threats.

SIGA Technologies Appoints Dr. Diem Nguyen as New CEO Amidst Financial Challenges

January 22, 2024



SIGA Technologies, Inc. (SIGA), a prominent pharmaceutical company specializing in the health security market, has recently shared news of the appointment of Dr. Diem Nguyen as their new Chief Executive Officer (CEO). With expertise encompassing a Ph.D. and an MBA, Dr. Nguyen s arrival is anticipated to bring fresh perspective and drive growth for SIGA starting January 27, 2024. Concurrently, the current CEO, Dr. Phil Gomez, will step down from his position the day before, marking the beginning of a new era for the company.
Financial Performance Overview:
Despite the forthcoming leadership transition, SIGA Technologies faces a significant challenge with its financial performance. In the twelve months leading up to the third quarter of 2023, SIGA recorded a cumulative net loss of $-5 million, resulting in a negative return on investment (ROI) of -3.37%. This underwhelming performance places SIGA behind 141 other companies in the healthcare sector that displayed stronger returns on investment. Moreover, the company s total ranking in terms of ROI has considerably deteriorated from 244 to 1837 compared to the second quarter of 2023.






Financial Statements
Siga Technologies Inc's III. Quarter Investments $ 166 Millions SIGA's Balance sheet
Siga Technologies Inc's III. Quarter Income $ -3 Millions Quarterly SIGA's Income Statement
SIGA's Income by Division See SIGA's Income by Division


SIGA Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 201 219 200 174 184
Y / Y Investment Growth -8 % 9.37 % 15.4 % -5.82 % 32.21 %
Net Income in Millions 23 59 68 34 69
Y / Y Net Income Growth -60.69 % -13.01 % 100.76 % -51.18 % 23.27 %
Annual Return On Investment 11.55 % 27.04 % 33.99 % 19.54 % 37.7 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 11.55 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SIGA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SIGA's Competitors
Subscribers only: Roi for Siga Technologies Inc's Suppliers
Subscribers only: Return On Investment for SIGA's Customers

Other Ratios
SIGA's Roa SIGA's Inventory Turnover Ratio SIGA's Growth Rates SIGA's Dividend Statistics
SIGA's Profitability Ratios SIGA's Asset Turnover Ratio SIGA's Dividend Growth
SIGA's Roe SIGA's Valuation Ratios SIGA's Financial Strength Ratios SIGA's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Sanuwave Health Inc   16.50 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Amgen Inc   13.64 %
Carlisle Companies Incorporated  13.64 %
Bristol myers Squibb Company  13.59 %
3m Company  13.24 %
Alpha Pro Tech Ltd   13.18 %
Beone Medicines Ltd   13.17 %
Regeneron Pharmaceuticals Inc   13.00 %
Abbvie Inc   12.87 %
Lantheus Holdings Inc   11.96 %


Date modified: 2026-11-10T13:47:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.